A recent article in the NY Times raises the question about the ethics of conducting clinical trials outside the US when these studies are meant to gather evidence for drug approval in the country.
The article which was written by several Duke University researchers and was published in the New England Journal of Medicine discusses how medication that is intended for the wealthy should not be tested on people in developing countries. The report questions whether or not testing drugs in developing countries is even relevant to American patients.
What are your thoughts?
About:
The Partnerships in Clinical Trials Blog focuses optimization intelligence, regulatory trends and globalization strategies for both as sponsors and CROs. It is an extension of the Partnerships in Clinical Trials Conference.
As a reader of the Partnerships in Clinical Trials blog, mention code XP1718BLOG when registering to join us in Sao Paulo for Partnerships in Clinical Trials Latin America to receive a discount of $100 off the current rate!
Would you like to guest blog on our site? Or send us feedback? Send an email to jpereira@iirusa.com.



.gif)
0 comments:
Post a Comment